Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab, Bortezomib, and Dexamethasone in Multiple Myeloma with Severe Kidney Disease
NCT04912427Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2022
- Primary completion
- Dec 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of isatuximab in multiple myeloma (MM), sponsored by Washington University School of Medicine. Started Apr 2022; status: terminated.
02
Drugs
isatuximab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04912427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04912427.